Mateon Therapeutics, Inc, a US based developer of TGF-β therapeutics for oncology and infectious diseases, has announced that it has launched its artificial intelligence (AI) telemedicine platform for post marketing survey (PMS) to support the launch of its drug product, PulmoHeal^TM.

The PMS module, with its previously announced AI mobile app, ArtiHealth^TM, rounds out the company’s AI telemedicine solution.

The combination of the drug and telemedicine targets patients for respiratory health, including COVID-19, in India. Initially the drug and device combination will only be available in India through Indian partner, Windlas, with the drug marketed under brand name PulmoHeal^TM.

“Mateon's artificial intelligence (AI) telemedicine platform for post marketing survey (PMS), will provide large scale real world clinical data necessary for a systematic evaluation of PulmoHeal^TM in respiratory diseases such as COVID-19, COPD and asthma,” said Saran Saund, CBO, GM,  AI Division, Mateon.

The PMS platform is meant to collect large amount of real-world evidence for safety and efficacy that would be instrumental in disease expansion of PulmoHeal^TM.

“We are thrilled to launch PulmoHeal^TM for respiratory patients based on successful outcome of ARTI-19 interim data,” said Hitesh Windlas, MD, Windlas. 

The interim report of 60 patients of the ARTI-19 study found PulmoHeal^TM to be significantly effective by more than doubling the recovery rate of COVID-19 patients.

Mike Potts, VP, Artificial Intelligence (AI), Mateon, commented, "I am excited with the launch of our telemedicine PMS platform to support PulmoHeal^TM. We built this telemedicine platform to support future clinical studies and not for PulmoHeal alone.”

Amit Shah, CFO, Mateon, commented, "With our continued drive to remove inefficiencies from the drug development and clinical trials processes, the launch of the PMS telemedicine module sets the stage for continual improvement of drug development and clinical trials.”